Home > Healthcare > Medical Devices > Therapeutic Devices > Xenotransplantation Market

Xenotransplantation Market Share

Report ID: GMI6136
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Xenotransplantation Market Share

Some of the major market participants operating in the xenotransplantation market include

Novartis AG
Immerge BioTherapeutics, Inc.
United Therapeutics Corporation
Infigen, Inc.
eGenesis, Inc.
NZeno Limited
Preservation Solutions, Inc.
Xeno Transplants Corporation
F. Hoffmann-La Roche Ltd.
OrganOX Limited

Authors: Mariam Faizullabhoy , Pratiksha Kamthe

Frequently Asked Questions (FAQ) :

Global market for xenotransplantation was valued at USD 12.7 billion in 2022 and is estimated to account for USD 29.9 billion by 2032, backed by the ongoing R&D in genetic engineering, immunosuppressive therapies, and organ preservation technologies.

The transplant diagnostics segment garnered over USD 5.4 billion in 2022 owing to the growing chronic diseases burden worldwide that leads to surge in the number of organ failure cases.

U.S. market accounted for USD 7 billion in 2022 and will witness considerable market growth during 2023-2032, attributed to the growing prevalence of chronic diseases such as end-stage renal disease, heart failure, and liver failure in the region.

Novartis AG, Immerge BioTherapeutics, Inc., United Therapeutics Corporation, Infigen, Inc., eGenesis, Inc., NZeno Limited, Preservation Solutions, Inc., Xeno Transplants Corporation, F. Hoffmann-La Roche Ltd. and OrganOX Limited among others.